ArticleEuropean journal of epidemiology2016
Proton pump inhibitors and gastroenteritis.
Article in European journal of epidemiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 35 citations in OpenAlex.
- Use of Proton Pump Inhibitors and the Risk of Hospitalization for Infectious Gastroenteritis.PloS one · 2016Trial
- The effect of proton-pump inhibitor therapy on disease outcomes in inflammatory bowel disease: a population-based cohort study.Therapeutic advances in gastroenterology · 2025Article
- Gastric Acid Suppression Is Associated With Higher Rates of Colectomy in Patients With Inflammatory Bowel Disease.Gastro hep advances · 2025Review
- Proton pump inhibitors and gastrointestinal symptoms among patients with COVID-19 infection.Annals of medicine · 2024Article
- Vibrio parahaemolyticus Foodborne Illness Associated with Oysters, Australia, 2021-2022.Emerging infectious diseases · 2024Review
- Salivary microbiota composition before and after use of proton pump inhibitors in patients with laryngopharyngeal reflux: a self-control study.BMC oral health · 2024Article
- A Pharmacogenetics-Based Approach to Managing Gastroesophageal Reflux Disease: Current Perspectives and Future Steps.Pharmacogenomics and personalized medicine · 2023Review
- Association Between Proton Pump Inhibitor Use and Extended-Spectrum Beta-Lactamase Urinary Tract Infection in Adults: A Retrospective Study.Infection and drug resistance · 2023Article
- Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota.Frontiers in pharmacology · 2023Review
- Review
- Optimizing the Use of Medications and Other Therapies in Infant Gastroesophageal Reflux.Paediatric drugs · 2018Review
- Review
- Proton-pump inhibitors: understanding the complications and risks.Nature reviews. Gastroenterology & hepatology · 2017Review
- The Rotterdam Study: 2018 update on objectives, design and main results.European journal of epidemiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An association between proton pump inhibitor (PPI) therapy and bacterial gastroenteritis has been suggested as well as contradicted. The aim of this study was to examine the association between the use of PPIs and occurrence of bacterial gastroenteritis in the prospective Rotterdam Study. The Rotterdam Study is a population-based cohort study among 14,926 subjects aged 45 years and older with up to 24 years of follow-up. Analyses were performed with a generalized estimating equations method in participants who handed-in a diagnostic stool sample. Furthermore, a nested case-control analysis was performed using the total cohort as a reference group. A bacterial microorganism was isolated in 125 samples, whereas 1174 samples were culture negative. In the generalized estimating equations analysis, we found that participants with a bacterial gastroenteritis were more likely than controls to be current users of PPIs (adjusted OR 1.94; 95 % CI 1.15-3.25). Different sensitivity analyses did not change this result. A considerably higher effect was observed (adjusted OR 6.14; 95 % CI 3.81-9.91), using the total cohort as a reference in a nested case-control analysis. Current PPI therapy is associated with an increased risk of bacterial gastroenteritis. However, by reducing the risk of selection and information bias in our study design, we demonstrated that the effect is lower than previously assumed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.